Abstract
Annual influenza vaccination is recommended for persons with human immunodeficiency virus (HIV) infection. Recent reports indicate that immunizations may increase HIV replication in infected individuals. Generally, vaccination against influenza is well tolerated in both children and adult individuals with HIV and does not induce significant changes in viral load and CD4+ cell counts. The observed increase in viral replication is usually transient and a clear, measurable progression of the underlying HIV disease is hard to be determined. Several studies reported immunogenicity data in HIV+ population, by comparing different influenza vaccines, adjuvanted or not, and different administration routes. Data are encouraging because an adequate immune response is shown, although split/subunit vaccines do not elicite an efficient immune response in these subjects. New strategies have been evaluated to increase the immune response in immunocompromised patients.The aim of this review is to evaluate tolerability, safety, immunogenicity and efficacy of vaccines actually approved for human use and to consider latest evidence and future perspective in HIV positive subjects.
| Original language | English |
|---|---|
| Pages (from-to) | 1-10 |
| Number of pages | 10 |
| Journal | Journal of Preventive Medicine and Hygiene |
| Volume | 54 |
| Issue number | 1 |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Cd4+ count
- Hiv-1 rna levels
- Influenza vaccination
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Cite this
Influenza vaccination in hiv-positive subjects : Latest evidence and future perspective. / Ceravolo, Antonella; Orsi, A.; Parodi, V.; Rosselli, R.; Ansaldi, F.
In: Journal of Preventive Medicine and Hygiene, Vol. 54, No. 1, 2013, p. 1-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Influenza vaccination in hiv-positive subjects
T2 - Latest evidence and future perspective
AU - Ceravolo, Antonella
AU - Orsi, A.
AU - Parodi, V.
AU - Rosselli, R.
AU - Ansaldi, F.
PY - 2013
Y1 - 2013
N2 - Annual influenza vaccination is recommended for persons with human immunodeficiency virus (HIV) infection. Recent reports indicate that immunizations may increase HIV replication in infected individuals. Generally, vaccination against influenza is well tolerated in both children and adult individuals with HIV and does not induce significant changes in viral load and CD4+ cell counts. The observed increase in viral replication is usually transient and a clear, measurable progression of the underlying HIV disease is hard to be determined. Several studies reported immunogenicity data in HIV+ population, by comparing different influenza vaccines, adjuvanted or not, and different administration routes. Data are encouraging because an adequate immune response is shown, although split/subunit vaccines do not elicite an efficient immune response in these subjects. New strategies have been evaluated to increase the immune response in immunocompromised patients.The aim of this review is to evaluate tolerability, safety, immunogenicity and efficacy of vaccines actually approved for human use and to consider latest evidence and future perspective in HIV positive subjects.
AB - Annual influenza vaccination is recommended for persons with human immunodeficiency virus (HIV) infection. Recent reports indicate that immunizations may increase HIV replication in infected individuals. Generally, vaccination against influenza is well tolerated in both children and adult individuals with HIV and does not induce significant changes in viral load and CD4+ cell counts. The observed increase in viral replication is usually transient and a clear, measurable progression of the underlying HIV disease is hard to be determined. Several studies reported immunogenicity data in HIV+ population, by comparing different influenza vaccines, adjuvanted or not, and different administration routes. Data are encouraging because an adequate immune response is shown, although split/subunit vaccines do not elicite an efficient immune response in these subjects. New strategies have been evaluated to increase the immune response in immunocompromised patients.The aim of this review is to evaluate tolerability, safety, immunogenicity and efficacy of vaccines actually approved for human use and to consider latest evidence and future perspective in HIV positive subjects.
KW - Cd4+ count
KW - Hiv-1 rna levels
KW - Influenza vaccination
UR - http://www.scopus.com/inward/record.url?scp=84888214326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888214326&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84888214326
VL - 54
SP - 1
EP - 10
JO - Journal of Preventive Medicine and Hygiene
JF - Journal of Preventive Medicine and Hygiene
SN - 1121-2233
IS - 1
ER -